The influence of hydroxyethyl starch on exogenous coagulation and active protein C in patients with septic shock

Chinese Critical Care Medicine

Volumn 27, Issue 1, 2015, Pages 28-32

  Jie, Lyu ^a   Tong, Li ^a   Fang, Liu ^a   Youzhong, An ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Active protein C; Exogenous coagulation; Hydroxyethyl starch; Ringer lactate solution; Septic shock

Indexed keywords

ACTIVE PROTEIN C; HETASTARCH; PROTEIN C; RINGER LACTATE SOLUTION; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION; RINGER'S LACTATE;

ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; FLUID RESUSCITATION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; BLOOD CLOTTING TEST; CHINA; DRUG EFFECTS; FLUID THERAPY; PROCEDURES; RESUSCITATION; SEPSIS; SHOCK, SEPTIC;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; CHINA; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; INTENSIVE CARE UNITS; ISOTONIC SOLUTIONS; LENGTH OF STAY; PROSPECTIVE STUDIES; PROTEIN C; RESUSCITATION; SEPSIS; SHOCK, SEPTIC;

EID: 84965087615     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.2095-4352.2015.01.007     Document Type: Article

References (19)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2013, 39(2):165-228.
2. Park DW, Chun BC, Kim JM, et al. Epidemiological and clinical characteristics of community-acquired severe sepsis and septic shock: a prospective observational study in 12 university hospitals in Korea[J]. J Korean Med Sci, 2012, 27(11):1308-1314.
3. Esmon CT. The impact of the inflammatory response on coagulation [J]. Thromb Res, 2004, 114(5-6):321-327.
4. Yokoyama T, Suwa K, Yamasaki F, et al. Intraoperative infusion of acetated Ringer solution containing glucose and ionized magnesium reduces ketogenesis and maintains serum magnesium[J]. Asia Pac J Clin Nutr, 2008, 17(3):525-529.
5. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis [J]. N Engl J Med, 2008, 358(2):125-139.
6. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0. 42 versus Ringer's acetate in severe sepsis [J]. N Engl J Med, 2012, 367(2):124-134.
7. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care[J]. N Engl J Med, 2012, 367(20):1901-1911.
8. Shubin NJ, Monaghan SF, Ayala A. Anti-inflammatory mechanisms of sepsis[J]. Contrib Microbiol, 2011, 17:108-124.
9. Okajima K. SIRS and the coagulation of normality [J]. Rinsho Byori, 2000, 48(6):510-515.
10. Lu X, Zhao L, Xu YH. Low molecular weight heparin prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation[J]. Bosn J Basic Med Sci, 2013, 13(1):50-56.
11. Zhao D, Ding R, Mao Y, et al. Heparin rescues sepsis-associated acute lung injury and lethality through the suppression of inflammatory responses[J]. Inflammation, 2012, 35(6):1825-1832.
12. Guidet B, Martinet O, Boulain T, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0. 4 vs. 0. 9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study[J]. Crit Care, 2012, 16(3):R94.
13. Marx G, Pedder S, Smith L, et al. Resuscitation from septic shock with capillary leakage hydroxyethyl starch (130 kd), but not Ringer's solution maintains plasma volume and systemic oxygenation[J]. Shock, 2004, 21(4):336-341.
14. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch[J]. Thromb Haemost, 1997, 78(3):974-983.
15. Mole DJ, Hall A, McKeown D, et al. Detailed fluid resuscitation profiles in patients with severe acute pancreatitis[J]. HPB (Oxford), 2011, 13(1):51-58.
16. Novotny AR, Reim D, Assfalg V, et al. Mixed antagonist response and sepsis severity-dependent dysbalance of pro- and antiinflammatory responses at the onset of postoperative sepsis[J]. Immunobiology, 2012, 217(6):616-621.
17. de Jonge E, Dekkers PE, Creasey AA, et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia[J]. Blood, 2000, 95(4):1124-1129.
18. Opal SM, Palardy JE, Parejo NA, et al. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis[J]. Crit Care Med, 2001, 29(1):13-17.
19. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis[J]. N Engl J Med, 2001, 344(10):699-709.